TNF and myelodysplastic syndrome: Consistently, Velegraki et al. showed that lower-risk MDS patients had an increased number of TNFα-producing intermediate monocytes (CD14bright/CD16−, proinflammatory cells) and a lower number of classical monocytes (CD14bright/CD16−, with advanced phagocytic and tissue repair activity) [66].